Can a targeted drug be safely used in children with rare tumors?
NCT ID NCT07755826
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This study monitors the safety of repotrectinib, a targeted cancer drug, in children and adolescents aged 4 to under 18 with NTRK fusion-positive advanced or recurrent solid tumors. Researchers will track side effects during routine treatment, paying special attention to nervous system issues, lung problems, and fractures. The goal is to better understand the drug's safety profile in this younger population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- repotrectinib
- What this could lead to
- If successful, this study could provide reassurance about the safety of repotrectinib in children, supporting its use as a treatment option for NTRK fusion-positive tumors.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove effectiveness. Side effects may still occur, and the small number of participants limits generalizability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NTRK FUSION-POSITIVE SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMIC Co., Ltd.
RECRUITINGMinato-ku, Tokyo, 105-0023, Japan
-
EPS Corporation
RECRUITINGTokyo, Japan